Immunome

Update in progress

IMNM (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Immunome, Inc. is a biotechnology company focused on discovering and developing antibody-based therapies for cancer. It works on antibody-drug conjugates and other oncology treatments in the United States. Its clinical assets include Varegacestat, a gamma secretase inhibitor in Phase 3 for desmoid tumors, and IM-1021, a ROR1-targeted ADC in Phase 1. Preclinical programs include IM-3050 (FAP radioligand therapy) and solid-tumor ADCs IM-1617, IM-1340, and IM-1335. Based in Bothell, Washington, and founded in 2006.

Company score

Sentiment: 0.50; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.23; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.29; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqCM (NCM)
LocationUnited States
CEODr. Clay B. Siegall Ph.D.
Founded2006
Employees247
Websiteimmunome.com

Identifiers

ISINUS45257U1088
FIGIBBG00BR93ZG8
CUSIP45257U108
CIK0001472012